Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!

doi:10.4239/wjd.v13.i7.471

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4767)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

393

WORD

HTML

2611

Figures (1-1)

477

Tables (1-1)

255

Sum=3780

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

174

Download

352

Sum=526

Publishing Process of This Article

Item

Count

Browse

181

Download

280

Sum=461

Jul 15, 2022 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Jul 15, 2022; 13(7): 471-481
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.471

Open in New Tab Full Size Figure Download Figure

Figure 1 Major cardio-renal outcome trials in patients with diabetic kidney disease and type 2 diabetes mellitus. ARB: Angiotensin-receptor blocker; ACEI: Angiotensin converting enzyme inhibitors; DRI: Direct renin inhibitors; ERA: Endothelin A receptor antagonists; EXD: Experimental drugs; MRA: Mineralocorticoid receptor antagonists; PKC-βi: Protein-kinase C β inhibitor; SGLT-2i: Sodium-glucose co-transporter 2 inhibitors; TGF-βi: Tumor growth factor β inhibitor.

Citation: Singh AK, Singh R. Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades! World J Diabetes 2022; 13(7): 471-481
URL: https://www.wjgnet.com/1948-9358/full/v13/i7/471.htm
DOI: https://dx.doi.org/10.4239/wjd.v13.i7.471